Mergers and Acquisitions

Date: 2017-01-04

Type of information: Plant acquisition

Acquired company: peptides business and operations of Lonza in Braine-l’Alleud (Belgium)

Acquiring company: PolyPeptide Laboratories (Denmark)

Amount: undisclosed

Terms: • On January 4, 2017, Lonza has concluded the divestment of its Peptides Business located in Braine-l’Alleud, (Belgium) to PolyPeptide Laboratories Holding. The facility, with approximately 280 employees, was the center for peptide chemical development and manufacturing within Lonza. The intention to divest was announced at the beginning of December 2016. The financial terms of the transaction are not disclosed. As announced early December, Lonza has booked a non-cash related write-off of CHF 44 million. Furthermore, Lonza will also book a CHF 29 million non-cash currency translation impact in the first half of 2017.

Details:

• PolyPeptide Group announced that the harmonization of procedures at the Belgian facility to ensure consistency, continuity and quality within its expanded Group will be implemented in the coming months. The integration process is expected to be seamless to customers. Braine facility, with approximately 280 employees, is the center for peptide chemical development and manufacturing within the Lonza Group. This acquisition brings to PolyPeptide immediate access to additional large-scale capacity in synthesis, purification and isolation of peptides, while PolyPeptide’s large portfolio of late-stage products brings to the Lonza Braine facility new opportunities for growth and expansion.

Related: Manufacturing - Bioproduction

Is general: Yes